missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Nemolizumab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody
£397.00 - £1002.00
Specifications
| Antigen | Nemolizumab Humanized |
|---|---|
| Concentration | 1 mg/mL |
| Content And Storage | -20°C, Avoid Freeze/Thaw Cycles |
| Applications | ELISA, Flow Cytometry, Functional Assay |
| Classification | Recombinant Monoclonal |
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
|---|---|---|---|---|---|---|---|---|---|
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
30283978
![]() |
Invitrogen™
MA558665 |
100 μg |
£397.00
100µg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
|
30282987
|
Invitrogen™
MA558666 |
1 mg |
£1002.00
1mg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Nemolizumab is a biosimilar that targets IL31RA. IL-31 is a T cell cytokine that is preferentially produced by T helper type 2 cells. IL-31 signals through a heterodimeric receptor composed of the IL-31 receptor (IL-31R) and the oncostatin M receptor (OSM). This receptor complex recruits JAK1, JAK2, Stat1, Stat3 and Stat5 signaling pathways, as well as the pi3 kinase/AKT cascade. SHP-2 and Shc adapter molecules are also recruited and contribute to an increased activation of the MAP kinase pathway in response to IL-31. Overexpression of IL-31 in mice results in pruritus and skin dermatitis resembling human atopic dermatitis (AD). Comparisons between skin from patients with AD and healthy skin showed IL-31R expression at higher levels on epidermal keratinocytes in AD samples. Infiltrating cells, more numerous in skin from patients with AD compared with that of healthy individuals, expressed IL-31 mRNA. IL-31 may participate in the cause of itch sensation and promote scratching behavior in NC/Nga mice with atopic dermatitis, and may represent a novel target for antipruritic drug development.Specifications
| Nemolizumab Humanized | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Recombinant Monoclonal | |
| Lyophilized | |
| IgG2 κ | |
| Human | |
| CIM 331 | |
| Antibody |
| 1 mg/mL | |
| ELISA, Flow Cytometry, Functional Assay | |
| Unconjugated | |
| Human | |
| RUO | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Primary | |
| Protein A |
Spot an opportunity for improvement?Share a Content Correction
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title